Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YKYamuna KondapallyJFJulie FortierMFMark A. Fiala

Discussion

Loading...

Member takes

Overview

Pilot study reports improved monitoring of measurable residual disease in multiple myeloma, suggesting potential benefits of ctDNA assays over conventional methods.

Key Points

  • ctDNA testing detected all baseline samples in the cohort of 8 patients, showing its high initial feasibility in monitoring.
  • At day +100, 25% of patients were ctDNA-positive, but all ctDNA-negative patients remained relapse-free for over a year post-transplant.
  • Whole-exome sequencing was performed for tracking tumor-specific variants to create personalized assays for each patient.
  • Results indicate that additional research is needed to evaluate the effectiveness of ctDNA monitoring compared to traditional methods.

Cite This Study

Kondapally et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7ddhttps://doi.org/10.1182/blood-2025-2219
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025
  2. 2Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas2025 · 1 citations
  3. 3Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing2026 · 1 citations
  4. 4Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant2025
  5. 5A plasma-based test for the measurable residual disease informs the response to treatment in AML patients2025